Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s share price rose 2.8% on Thursday . The company traded as high as $5.29 and last traded at $5.20, with a volume of 1,118,501 shares traded. The stock had previously closed at $5.06.

PGNX has been the topic of a number of recent research reports. Brean Capital restated a “buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Tuesday, March 15th. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Friday, June 10th. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Progenics Pharmaceuticals in a report on Monday, April 4th. Finally, BTIG Research decreased their target price on shares of Progenics Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, March 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $10.35.

The company has a 50-day moving average of $4.70 and a 200 day moving average of $4.74. The company’s market cap is $380.51 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $3.27 million. During the same period last year, the business earned ($0.15) EPS. The firm’s revenue for the quarter was up 908.1% on a year-over-year basis. Equities research analysts anticipate that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.